bpc 157 и tb 500 BPC-157 + TB-500 Research Compound Capsules BPC157 & TB500 Blend (10mg/10mg)

Standard Protocol (Targeted Repair/Systemic Research): A dosage of 500 mcg per day, often split into two doses of 250 mcg each (one in the morning, one at night), is the most prevalent protocol we see

No request needed

Manufactured in a UK-Based Laboratory Synthesised under stringent scientific protocols

(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement